CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals

Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped CStone post its first-ever significant revenues and narrowing losses in 2020 The company is eying new approvals for more uses of its cancer drugs as big-name global pharma companies pump it up with cash By Richard Barbarossa CStone Pharmaceuticals Co. Ltd (2616.HK), a Chinese maker of immuno-oncology therapies and precision medicines, is moving closer to profitability after its losses narrowed…

Read MORE »